The Enterprise Value as of September 2024 (TTM) for Verona Pharma plc (VRNA) is 1.95B

According to Verona Pharma plc’s latest financial reports and current stock price. The company's current Enterprise Value is 1.95B. This represents a change of 69.84% compared to the average of 1.15B of the last 4 quarters.

Verona Pharma plc (VRNA) Historical Enterprise Value (quarterly & annually)

How has VRNA Enterprise Value performed in the past?

The mean historical Enterprise Value of Verona Pharma plc over the last ten years is 4.89B. The current 1.95B Enterprise Value has changed 3.90% with respect to the historical average. Over the past ten years (40 quarters), VRNA's Enterprise Value was at its highest in in the September 2022 quarter at 6.73B. The Enterprise Value was at its lowest in in the June 2014 quarter at -20607693.00.

Verona Pharma plc (VRNA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Verona Pharma plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Verona Pharma plc (VRNA) Average Enterprise Value

How has VRNA Enterprise Value performed in the past?

The current Enterprise Value of Verona Pharma plc (VRNA) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Verona Pharma plc (VRNA) Enterprise Value vs. Peers

How is VRNA’s Enterprise Value compared to its peers?

Verona Pharma plc’s Enterprise Value is greater than Ventyx Biosciences, Inc. (123.69M), less than IDEAYA Biosciences, Inc. (2.88B), less than Protagonist Therapeutics, Inc. (2.10B), greater than Syndax Pharmaceuticals, Inc. (1.52B), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than Inozyme Pharma, Inc. (343.89M), greater than Acumen Pharmaceuticals, Inc. (93.64M), greater than Mereo BioPharma Group plc (582.99M), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Amylyx Pharmaceuticals, Inc. (89.50M), less than MoonLake Immunotherapeutics (2.55B), less than Mirati Therapeutics, Inc. (3.91B), less than Apellis Pharmaceuticals, Inc. (5.11B), greater than Akero Therapeutics, Inc. (1.56B), less than Madrigal Pharmaceuticals, Inc. (4.91B), less than Viking Therapeutics, Inc. (5.95B),

Build a custom stock screener for Verona Pharma plc (VRNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verona Pharma plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Verona Pharma plc (VRNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Verona Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.